Evidence map›Paper›PMID 42259836›Full record

ArticleScientific reports2026

Comparative analysis of the sputum microbiota in different COPD clinical states.

Lamis Galal, Mohamed A Eltokhy, Heba M Abostate, Maha Eid Omran, Sahar M R Radwan

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lamis Galal *Microbiology and Immunology Department, Faculty of Pharmacy , Girls Al-Azhar University, Cairo, Egypt.
Mohamed A EltokhyDepartment of Immunotherapeutics and Biotechnology, Center for Tumor Immunology and Targeted Cancer Therapy, Texas Tech University Health Sciences Center, Abilene, TX, 79601, USA.
Heba M Abostate *Microbiology & Immunology Department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.
Maha Eid Omran *Microbiology and Immunology Department, Faculty of Pharmacy , Girls Al-Azhar University, Cairo, Egypt.
Sahar M R RadwanMicrobiology and Immunology Department, Faculty of Pharmacy , Girls Al-Azhar University, Cairo, Egypt. saharradwan561.el@azhar.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a well-known respiratory illness. COPD patients oscillate between a stable state and an exacerbated state that leads to disease deterioration. Studies suggest that respiratory microbiome dysbiosis plays a vital role in COPD pathogenesis. However, the exact microbial composition among different clinical states of COPD is still elusive. To determine and compare the respiratory microbiota composition in different COPD clinical states, namely, the stable state (S-COPD) and the acute exacerbated state (AE-COPD). In this prospective study, 74 samples were collected from COPD patients. The sputum microbiota was analyzed via 16 S rRNA gene sequencing, and only 35 samples were included due to bad reads or not in accordance with inclusion criteria: S-COPD patients (n = 18), and AE-COPD patients (n = 17). Bioinformatics analysis was used to determine changes in the microbiota among the comparison groups. The most abundant phyla among all the samples were Proteobacteria, Fusobacteria, Firmicutes, and Actinobacteria, with Paracoccus, Streptomyces Leptotrichia Fusobacterium and Ruminococcaceae being the most prevalent genera. Dissimilarity in abundance across the studied COPD states was observed, with significantly greater abundance of Proteobacteria and Fusobacteria in S-COPD patients and greater abundance of Firmicutes in AE-COPD patients at the phylum level. At the genus level, Paracoccus, Fusobacterium, Streptococcus, Haemophilus, and Moraxella were significantly different between the two groups and were more prevalent in S-COPD, whereas Cellulosilyticum, Streptomyces, Leptotrichia, Ruminococcaceae_UCG_014, and Atopobium were more prevalent in exacerbated individuals. Alpha diversity revealed greater diversity in stable versus exacerbated patients, and a PCoA plot of Bray‒Curtis and weighted UniFrac distances revealed that stable patients were highly clustered, whereas exacerbated patients were more disseminated. At the genus level, LEfSe analysis revealed the dominance of Cellulosilytic, Liptotrichia, and Streptomyces in the AE-COPD group, whereas the S-COPD group microbiome was dominated by the genera Paracoccus, Fusobacterium, Streptococcus Haemophilus, and Moraxella (p < 0.05). The results of the present study suggest that COPD patients have unique microbial profiles that differ across different states, with increased abundances of Proteobacteria, chiefly Paracoccus. These findings need more research to clarify the definite role of microbiome dysbiosis in COPD pathogenesis.

Indexed as

MicrobiotaPulmonary Disease, Chronic ObstructiveSputumAgedBacteriaFemaleHumansMaleMiddle AgedProspective StudiesRNA, Ribosomal, 16SRNA, Ribosomal, 16SCOPDExacerbation microbiomeParacocusProteobacteria

Identifiers

PMID42259836
PMCPMC13246853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.